Second Ovulation Induction

Outcomes From Secondary Ovulation Induction Following Failed Oocyte Pick-up IVF Cycles

Studies reported various risk factors for inadequate ovulation induction such as body mass index, low ovarian reserve, low baseline FSH and LH, and previous use of contraception or agonist.

The flexibility to use human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonist (GnRHa) in ovulation induction for antagonist protocol or progestin primed ovarian stimulation (PPOS) is an advantage helping fertility doctors to decrease the risk of ovarian hyperstimulation syndrome. However, luteinizing hormone (LH) levels <15UI/L and progesterone ≤11.13nmol/L eight to twelve hours post GnRHa trigger were highly correlated to failed oocyte pickup (FOP).

Rescue hCG have been found to increase favorable outcomes in patients with FOP. The presence of false FOP could be due pharmaceutical reasons and human error. Genuine FOP could be due to intrinsic ovarian pathology.

The FOP is defined as the absence of oocytes after ovarian stimulation and follicular aspiration. It is an uncomfortable situation for the patient and medical team to deal with due to the apparent expectations of favorable results.

Ovulation induction could be via GnRHa, HCG, or both in antagonist protocol and PPOS protocol. Long or short agonist protocol could be triggered only via HCG.

Study Overview

• Status: Completed
• Conditions: Infertility; IVF
• Intervention / Treatment: Other: Women having had second ovulation induction after failed oocyte pick-up

• Study Type: Observational
• Enrollment (Actual): 87

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H4P 2S4
      • Clinique ovo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Electronic medical record from 2018 to 2023 of patients having undergone an IVF cycle

Description

Inclusion Criteria:

• Participants with no oocytes retrieved in the first ovum pick-up

Exclusion Criteria:

• Error in trigger medication or timing by the patient/ medical team
• Major absence of information (primary objective, trigger medication, time interval of trigger and ovum pick-up

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oocyte pick-up at retrieval	Number of retrieved oocytes after second ovulation induction in patients with FOP	36 hours after ovulation triggering

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Timing of ovulation triggering	Time interval outcomes between trigger and ovum pickup	24 to 36 hours after ovulation triggering

Collaborators and Investigators

• Sponsor: Clinique Ovo
• Investigators: Principal Investigator: Simon Phillips, PhD, Clinique ovo

Study record dates

Study Major Dates

• Study Start (Actual): July 4, 2024
• Primary Completion (Actual): July 30, 2024
• Study Completion (Actual): May 20, 2025

Study Registration Dates

• First Submitted: July 9, 2024
• First Submitted That Met QC Criteria: July 9, 2024
• First Posted (Actual): July 16, 2024

Study Record Updates

• Last Update Posted (Estimated): September 10, 2025
• Last Update Submitted That Met QC Criteria: September 3, 2025
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Infertility
• Other Study ID Numbers: 3572

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No